ClinicalTrials.gg
CompletedNCT018455582012-005003-40Updated Aug 28, 2015

Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise

A Phase 4 interventional study of Wobenzym® plus and Placebo in Muscle Injury, Muscle Soreness and Exercise Induced Muscle Damage, sponsored by Mucos Pharma GmbH & Co. KG. Completed at 1 site in Germany. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-28.

Sponsored by Mucos Pharma GmbH & Co. KG · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

The aim of the current study is to investigate the therapeutic effect and especially the mode of action of Wobenzym® plus, an anti-inflammatory drug containing proteolytic enzymes, on exercise induced muscle damage (eiMD) and recovery time in male amateur sportsmen with medium proficiency level compared to placebo.

02

Conditions studied

  • Muscle Injury
  • Muscle Soreness
  • Exercise Induced Muscle Damage

Keywords

  • Muscle soreness
  • Exercise induced muscle damage
  • Inflammation
  • Proteolytic enzymes
  • Muscle strength Dynamometer
03

In context

Myalgia

256 studies on the registry are indexed under Myalgia; 46 are open to participants now.

This study's enrollment of 69 is above the median of 44 across 216 interventional studies indexed under Myalgia.

Browse Myalgia studies →

Lead sponsor

Mucos Pharma GmbH & Co. KG is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able and willing to sign the Form prior to screening evaluations
  • Subject is in good physical and mental health as established by medical history, physical examination, , vital signs, results of biochemistry, haematology
  • Not anticipating any planned changes in lifestyle regarding activity and nutrition for the duration of the study
  • Non smoker
  • Men with strength training experience
  • Age: 20-50 years
  • ≥20 kg/m2 and ≤ 32 kg/m2
  • medium concentric strength ability (150-300 Nm)

Exclusion criteria

Exclusion Criteria:

  • Relevant history or presence of any medical disorder, potentially interfering with this trial (e.g. volunteers having experienced any cardiovascular events such as infarction, angina, surgical endocoronary intervention, stroke or volunteers suffering from diabetes as well as acute or chronic injury of the musculoskeletal system, e.g. cruciate ligament rupture.
  • No intake of anti-inflammatory medication/ food supplements or intake of medications that directly affect parameters of muscle function or performance within 4 weeks prior to visit 1 or during the trial
  • Subjects not willing to abstain from intake of analgesic medication 24 hours prior to and during visit 1 and 2.
  • For this trial abnormal laboratory, vital signs or physical findings at screening
  • Known to the study preparation or to single ingredients (e.g. Lactose intolerance)
  • Drug, alcohol and/or medication abuse
  • Known -infection
  • Known acute or chronic and C infection
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Blood donation within 4 weeks prior to trial start (visit 1) or during trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Wobenzym® plus

    Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)

    Drug: Wobenzym® plus

  • Placebo comparator
    Placebo equates Wobenzym® plus but without active ingredients

    3x4 capsules/ day

    Other: Placebo

Interventions

  • DrugWobenzym® plus
  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Reduction of maximal concentric strength, movement induced pain and pressure induced pain combined in a multidimensional (composite outcome)model giving information about the change induced by the stress test

    Multidimensional approach for recovery and acute phase after eccentric stress test. Will be assessed at different time points before and after an excentric stress test and the reduction of these parameters under treatment will be calculated.

    Time frame: immediately before, 24h post, 48h post

Secondary outcomes

  1. Maximal concentric strength (Nm) before and after the stress test

    Reduction of strength induced by the excentric stress test

    Time frame: immediately before, 0h, 3h, 6h, 24h, 48h, 72h

  2. Pressure induced pain

    Pain induced by the stress test rated via Algometry kg/cm\*cm induced by standardised pressure

    Time frame: immediately before, 0h, 3h, 6h, 24h, 48h, 72h

  3. Blood routine parameters

    Blood routine parameters (differentiated haemogram; blood lipids; glucose; kreatinin) as safety parameters

    Time frame: immediately before, 0h, 3h, 6h, 24h, 48h, 72h

  4. blood pressure

    Blood pressure and heart rate as safety parameter

    Time frame: immediately before, 24h, 48h, 72h

  5. Movement induced pain

    Pain induced by a standardised movement and rated by the volunteer via VAS.

    Time frame: immediately before, 0h, 3h, 6h, 24h, 48h, 72h post

07

Study locations

1 site
  • Sportschule FFb Puch GmbH
    Fürstenfeld Bruck, 82256, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2013
First posted
May 3, 2013
Start
Feb 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Last update
Aug 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01845558
Lead sponsor
Mucos Pharma GmbH & Co. KG
Responsible party
Sponsor
First posted
May 3, 2013
Start date
Feb 2013
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Aug 28, 2015

Study contacts

Helmut Pabst, Dr. med
principal investigator · PWC GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion